ABSTRACT
The basic concept supporting the intraperitoneal administration of cytotoxic (or biological) agents in ovarian cancer is rather simple: administer the drug(s) at higher concentrations and for more prolonged periods of time than possible with systemic drug delivery. In essence, intraperitoneal treatment can be viewed as a regional attempt to increase dose intensity and/or the duration of exposure of cancer cells to cycle-specific antineoplastic drugs (1,2).
